Background Artemisinins, the most eff ective antimalarials available, are not recommended for falciparum malaria during the fi rst trimester of pregnancy because of safety concerns. Therefore, quinine is used despite its poor eff ectiveness. Assessing artemisinin safety requires weighing the risks of malaria and its treatment. We aimed to assess the eff ect of fi rst-trimester malaria and artemisinin treatment on miscarriage and major congenital malformations.
Introduction
The associations between fi rst-trimester malaria, treatment, and miscarriage remain poorly documented because these events often occur before women present to antenatal care.
1,2 A single fi rst-trimester malaria episode is associated with miscarriage, 3 and women with fi rst-trimester malaria who are not adequately treated are at high risk of placental malaria. 4 Because women are usually not protected by preventive interventions until the second trimester, 3 early diagnosis and eff ective treatment of fi rst-trimester malaria are essential to limit the deleterious eff ects of malaria. 5 Artemisinin derivatives (hereafter referred to as artemisinins) are the most eff ective antimalarials available. Artemi sinin-based combination therapies are recommended by the WHO for fi rst-line treatment of falciparum malaria, except during the fi rst trimester of pregnancy. 6 Animal studies have raised concerns about the safety of artemisinins in the fi rst trimester, but data for human beings are scarce. In animals, artemisinins are embryotoxic and teratogenic because they deplete embryonic erythroblasts, causing miscarriage and congenital malformations (mainly cardiovascular and skeletal). 7 If artemisinins are also embryotoxic or teratogenic in human beings, the embryo-sensitive period is predicted to be between 6 weeks' and 13 weeks' gestation when erythroblasts are the primary form of circulating red blood cells. 8 Because of these safety concerns, quinine is still recommended for uncomplicated fi rst-trimester falciparum malaria rather than artemisinins, despite being an inferior treatment. 6 Available data for fi rst-trimester artemisinin safety comes from observational studies of inadvertent treatments, which are common but rarely documented. 2 No specifi c adverse eff ects have been noted in human beings in 935 documented fi rst-trimester artemisinin treatments (appendix p 1), [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] which although reassuring, has not been suffi cient to change treatment recommendations. 6 The Shoklo Malaria Research Unit (SMRU) screens pregnant women frequently for malaria because there are no eff ective preventive interventions (appendix p 3). 19 See Online for appendix Since 1986, prospective data have been collected on confi rmed malaria infections, antimalarial treatment, and pregnancy outcomes of women attending SMRU antenatal clinics, providing an important source of observational evidence on fi rst-trimester artemisinin safety. In this setting, a single fi rst-trimester malaria episode (falciparum or vivax) increased the odds of miscarriage, but fi rst-trimester artemisinin treatment was not associated with miscarriage. 3 However, for analytic clarity in this earlier study women with recurrent infections were excluded, which reduced the number of artemisinin treatments to 44 and overestimated the eff ect of malaria, because a recurrent infection in pregnancy depends on the fetus surviving the initial infection. Here, we extend this seminal study by including women with recurrent malaria, which might be either novel, recrudescent, or a relapse in the case of vivax malaria, and added 3 further years of data. Assessment of the safety of artemisinins requires weighing the risks of malaria and its treatment. Therefore, we sought to assess the eff ect of both fi rst-trimester malaria and artemisinin treatment on miscarriage and major congenital malformations.
Methods

Study design and participants
In this observational study, we assessed data from antenatal clinics on the Thai-Myanmar border between Jan 1, 1994, and Dec 31, 2013. We included women who presented to antenatal clinics during their fi rst trimester with a viable fetus. Women were screened for malaria, and data for malaria, antimalarial treatment, and birth outcomes were collected. The Oxford Tropical Research Ethics Committee granted ethical approval for audits of SMRU clinical records (OXTREC 28-09), and the Tak Province Community Ethics Advisory Board provided local permission (T-CAB-4/1/2015). Data for fi rst-trimester malaria from some of the records included in this analysis have been published previously.
3,19-22
Procedures
At SMRU antenatal clinics, women are encouraged to present early and return weekly throughout their pregnancy for malaria screening, consisting of a fi ngerprick blood sample that is examined by trained microscopists using Giemsa stained thick and thin blood fi lms (appendix p 3). 5 Women are also encouraged to present if they feel unwell, and to deliver at SMRU clinics. The fi rst consultation involves taking obstetric and medical histories, a detailed clinical examination, and gestational age estimation. 23 With each positive screen, information about species, parasitaemia, symptoms, and treatment are recorded. Women are also asked about recent antimalarial treatments at outpatient clinics, and these treatments (usually
Research in context
Evidence before this study We searched Scopus and PubMed for articles published up to Oct 5, 2015 , in any language, that addressed the association between fi rst-trimester artemisinin treatment and miscarriage using the search terms: "malaria or plasmodium", "pregnan*", "*artemisinin* OR ACT* OR artesunate OR artemether OR Coartem", "fi rst-trimester OR 'fi rst trimester' OR 'early pregnancy'", and "miscarriage* OR abortion". One study reported on the association between a single fi rst-trimester malaria episode and miscarriage. No randomised controlled trials of fi rst-trimester artemisinin treatment were identifi ed. No studies have reported on the association between recurrent fi rst-trimester malaria and miscarriage. Ten observational studies of fi rst-trimester artemisinin treatment were identifi ed totalling 935 documented treatments, and a systematic review published in 2007. These studies showed no evidence of an increased risk of miscarriage or major congenital malformations associated with fi rst-trimester artemisinin treatment. Importantly, only one published study examining the association between fi rst-line artemisinin treatment and miscarriage accounted for left truncation, which is necessary when women present at varying gestations due to the declining risk of miscarriage as a pregnancy progresses, and few were able to account for confounding by indication and disease severity.
Added value of this study
Assessment of the safety of artemisinin derivatives requires weighing the risks of falciparum malaria against those of its treatment. We noted that fi rst-trimester falciparum malaria increases the risk of miscarriage, especially after recurrence. However, there was no evidence that fi rst-line treatment with an artemisinin derivative in the fi rst trimester was associated with an increased risk of miscarriage or congenital malformations compared with fi rst-line quinine, which is currently recommended by the WHO. We compared fi rst-line treatment with an artemisinin derivative with fi rst-line quinine in women with fi rst-trimester falciparum malaria in an area of low seasonal transmission, and accounted for confounding by indication and disease severity, thereby separating the eff ects of infection from the eff ects of treatment. To the best of our knowledge, this study is the fi rst to estimate the association between recurrent fi rst-trimester malaria and miscarriage, and contributes a further 183 documented fi rst-trimester artemisinin treatments. Left truncation, which adjusts for the temporally changing risks of miscarriage and varying gestation at presentation, was also accounted for and is essential to avoid signifi cant bias.
Implications of all the available evidence
Eff ective treatment of fi rst-trimester falciparum malaria is imperative. Our results add to a growing body of observational evidence that artemisinins, the most eff ective antimalarials available, are safe in the fi rst trimester of pregnancy.
mefl oquine-artesunate [MAS] for P falciparum) are recorded retrospectively. Presumptive malaria treatment is not used, and pregnancy termination is unavailable.
First-trimester non-malaria febrile morbidity was defi ned as fever (temperature ≥37·5 o C) not associated with malaria. Malaria was defi ned as the presence of asexual stages of plasmodia parasites in the peripheral blood, counted per 500 white blood cells or 1000 red blood cells. Hyperparasitaemia was defi ned as 4% parasitaemia or greater, and severe malaria was defi ned according to signs of vital organ dysfunction. Symptomatic malaria was defi ned as patent parasitaemia and a history of fever (past 48 h) or temperature 37·5 o C or greater. Vivax malaria was treated with oral chloroquine. Falciparum malaria was treated with oral quinine in the fi rst trimester, or an artemisinin-based treatment in the second and third trimester (either artesunate, artemether-lumefantrine, dihydroartemisinin-piperaquine, or mefl oquine-artesunate). Mefl oquine monotherapy was given for falciparum malaria until 1996. Clindamycin was added to quinine and artesunate 7-day treatments in 2007 to augment effi cacy. According to WHO recommendations, artemisinins were given in the fi rst trimester for quinine failures, hyperparasitaemia, severe malaria, or if the fetus was no longer viable. 6 Details on treatment regimens and drug manufacturers are given in the appendix (p 4).
Outcomes
Primary exposures were malaria and fi rst-line artemisinin treatment in the fi rst trimester, defi ned as less than 14 weeks' gestation. The primary outcome was miscarriage, defi ned as fetal death before 28 weeks' gestation because infant respiratory support is unavailable. The ability to determine gestation and fetal viability at SMRU improved after ultrasound was introduced in 2002 (appendix p 3). 23, 24 The date of miscarriage was recorded consistently as the date of expulsion of the uterine contents, either spontaneously or through surgical intervention, which can occur some time after intrauterine death. The secondary outcome was major congenital malformations. A surface examination was done on all newborns by trained staff ; a physician verifi ed all malformations, except for some early neonatal deaths. Artemisinin-based treatments were fi rst deployed in the general population in 1994. Therefore, we included women who presented to antenatal clinics during their fi rst trimester with a viable fetus between Jan 1, 1994, and Dec 31, 2013.
Statistical analysis
We used Cox proportional hazards models accounting for left truncation (appendix p 5) and time-varying exposures for all miscarriage analyses, with censoring at the gestation time of miscarriage, gestation time when last seen, or 28 weeks' gestation. To assess the association between malaria and miscarriage, women entered the analysis at the gestation time of their fi rst antenatal visit. Multivariable models adjusted for year of fi rst consultation, gravidity, smoking, and fi rst-trimester non-malaria febrile morbidity. To assess the association between fi rst-line artemisinin treatment and miscarriage (primary analysis), we included women with fi rst-trimester falciparum malaria, and compared fi rst-line quinine treatment (including quinine plus clindamycin) with fi rst-line mefl oquine monotherapy, artemisinin treatment (all derivatives) following quinine failure (ie, artemisinin rescue), and fi rst-line artemisinin treatment (all derivatives). Women entered the analysis at the gestation time of their fi rst falciparum malaria episode. Treatments given after determination of fetal non-viability were excluded. Multivariable models adjusted for year of fi rst consultation, disease severity pertaining to the fi rst falciparum malaria episode (asymptomatic, symptomatic, or hyperparasitaemic or severe), and fi rst-trimester nonmalaria febrile morbidity. The prevalence of major congenital malformation was described by fi rst-trimester falciparum malaria and fi rst-line treatment. Malformations were grouped by organ system to increase the likelihood of detecting teratogenic signals. 25 Data were analysed with Stata version 13 (StataCorp, College Station, TX, USA). 
Role of the funding source
The funding sources (The Wellcome Trust and The Bill & Melinda Gates Foundation) had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication. The corresponding author had full access to all data and had the fi nal responsibility in the decision to submit for publication.
Results
Between Jan 1, 1994 and Dec 31, 2013, 55 636 pregnant women presented to SMRU clinics, of whom 25 485 (46%) presented during their fi rst trimester with a viable fetus (fi gure 1). Of these, 2257 (10%) of 23 118 miscarried, 2367 (9%) of 25 485 were lost to follow-up before 28 weeks gestation, and 2558 (10%) of 25 485 had fi rst-trimester malaria (fi gure 1). Women with fi rst-trimester malaria were more likely to miscarry or be lost to follow-up and tended to present for antenatal care earlier, be younger, be primigravid, and smoke compared with women without fi rst-trimester malaria (all p<0·0001; table 1).
Of the 2558 women with fi rst-trimester malaria, 1207 (47%) had falciparum malaria, 1532 (60%) had vivax malaria, and 181 (7%) had both vivax and falciparum (either separate or mixed infections). Recurrent fi rsttrimester falciparum malaria occurred in 162 (13%) of 1207 women, and recurrent fi rst-trimester vivax malaria in 139 (9%) of 1532. Most (971 [80%] of 1207) women with fi rst-trimester falciparum malaria were treated initially with quinine and 183 (15%) of 1207 were treated initially with artemisinin (ie, fi rst-line artemisinin treatment; table 1). Of the 971 women who received fi rst-line quinine treatment, 129 (13%) were rescued with artemisinin (usually artesunate monotherapy or artesunate plus clindamycin) following recurrence. Of the 183 fi rst-line artemisinin treatments, 37 (20%) were for hyperparasitaemia (administered orally) or severe disease (administered parenterally). First-line treatment of fi rsttrimester falciparum malaria occurred at a median of 8·2 gestation weeks (IQR 5·3-11·1). Loss to follow-up was similar between antimalarial treatment groups, except women receiving mefl oquine-artesunate were less likely to be lost (p=0·0417; appendix p 6). Rates of falciparum malaria during pregnancy and miscarriage and the frequency of fi rst-line quinine and artemisinin treatments in fi rst trimester over time are shown in fi gure 2.
Of 1207 women with fi rst-trimester falciparum malaria, 165 (17% of 983 followed until 28 weeks') miscarried and 224 (19%) were lost to follow-up compared with 1963 (9%) of 20 978 and 1949 (9%) of 22 927 in women with no fi rsttrimester malaria, respectively. In multivariable analyses, the hazard of miscarriage increased 1·61-fold (95% CI 1·32-1·97; p<0·0001) with an initial fi rst-trimester falciparum malaria episode, and 3·24-fold (2·24-4·68; p<0·0001) with recurrent fi rst-trimester falciparum malaria (fi gure 3). This association was stronger in women with symptomatic falciparum malaria than in women with asymptomatic falciparum malaria (fi gure 2). A single fi rst-trimester hyperparasitaemic or severe falciparum malaria episode increased the hazard of miscarriage 4·21-fold (95% CI 2·43-7·29; p<0·0001; fi gure 3). An initial fi rst-trimester vivax malaria episode, either asymptomatic or symptomatic, increased the hazard of miscarriage slightly (fi gure 3). Recurrent symptomatic fi rst-trimester vivax malaria increased the hazard of miscarriage 2·44-fold (95% CI 1·01-5·88; p=0·0473; fi gure 3).
Of the 1207 women with fi rst-trimester falciparum malaria, 1179 (98%) had a known fi rst-line antimalarial treatment and a viable fetus at the time of treatment (fi gure 1 Data are median (IQR) [range] or n (%). Missing: gravidity, ten; smoking status, 2853; history of miscarriage, nine; haematocrit, 969; and miscarriage, 2367 (ie, lost to follow up before 28 weeks' gestation). Continuous variables were compared between groups using the Student's t test for normal distribution or the Mann-Whitney U test for skewed distribution. Categorical variables were compared with the χ 2 test. *In women followed until 28 weeks; women who miscarried presented for antenatal care 1·4 weeks earlier (p<0·0001), because early attendance increases the chances that a miscarriage will be detected. †Women lost to follow-up were slightly younger (p<0·0001), and were more likely to be primigravid (p<0·0001) and have fi rst-trimester malaria (p<0·0001; appendix p 6). NA=not applicable. (1) (2) (3) (4) include women that might have also had fi rst-trimester vivax, malariae, or ovale malaria. See appendix p 8 for associations in women with only fi rst-trimester falciparum malaria. Models for vivax malaria (5-6) exclude women who also had fi rst-trimester falciparum malaria. Models 2 and 5 exclude women with symptomatic malaria. Models 3 and 6 exclude women with asymptomatic infections. Model 4 excludes women with uncomplicated infections. Models were adjusted for year (by stratifi cation due to non-proportional hazards [p<0·001]), gravidity, current smoking status, and non-malaria febrile morbidity in fi rst trimester. Age and previous miscarriage were omitted from multivariable models due to collinearity with gravidity. Adjusted results for gravidity, current smoking status, and febrile morbidity in fi rst trimester are shown from Model 1. 146 women had recurrent fi rst-trimester falciparum malaria (136 had two and ten had three episodes). 13 women had recurrent (two) asymptomatic fi rst-trimester falciparum malaria. 81 women had recurrent symptomatic fi rst-trimester falciparum malaria (75 had two, and six had three episodes). 17 women had recurrent (two episodes) asymptomatic fi rst-trimester vivax malaria, and none miscarried. 38 women had recurrent (two) symptomatic fi rst-trimester vivax malaria. See appendix p 8 for a table version of this fi gure, including univariable associations.
quinine (including quinine plus clindamycin), 129 (11%) of 1179 received fi rst-line quinine followed by artemisinin (artemisinin rescue), 25 (2%) of 1179 received fi rst-line mefl oquine monotherapy, and 183 (16%) of 1179 received fi rst-line artemisinin. First-line artemisinin treatment was not associated with miscarriage when compared with women who received fi rst-line quinine only (HR 0·78 [95% CI 0·45-1·34]; p=0·3645; fi gure 4). Five (3%) of 183 women received two fi rst-trimester artemisinin treatments; one miscarried, and four delivered.
Because animal studies suggest a theoretical embryosensitive window in human beings of 6-13 weeks' gestation, we also estimated the association between fi rst-line artemisinin treatment and miscarriage before, during, and after this window. 9 First-line artemisinin treatments before the embryo-sensitive window were associated with a non-signifi cant decrease in the hazard of miscarriage (HR 0·54 [95% CI 0·25-1·15]; p=0·1108), whereas treatments during the embryo-sensitive window were not associated with a changed hazard of miscarriage (1·15 [0·46-2·87]; p=0·7602; fi gure 4).
Of note, a high proportion of women who received fi rstline mefl oquine-artesunate miscarried (15 [21%] of 71), and most miscarriages in the artemisinin treatment group (15 [63%] of 23) were in women who received mefl oquineartesunate specifi cally. Further, a third of women who received mefl oquine-artesunate during the embryosensitive window miscarried (eight [33%] of 24). However, this might be explained by the circumstances of this treatment: women received mefl oquine-artesunate from outpatient clinics (rather than antenatal clinics) where they presented because of illness before they became aware of their pregnancy. Additionally, mefl oquine-artesunate treat ments at outpatient clinics were given at earlier gestations than for the other treatments when women are at greater risk of miscarriage (mefl oquine-artesunate: †Anencephaly (treated at 10 weeks' gestation). ‡Microphthalmia (8 weeks'). §Heart defect (7 weeks'). ¶Cleft lip and palate (10 weeks'); cleft lip and palate (9 weeks'). ||Imperforated anus (6 weeks'). **Cleft lip and palate (14 weeks'). † †Polydactyly (12 weeks'); polydactyly (12 weeks'); syndactyly and talipes (11 weeks'); syndactyly (9 weeks'). ‡ ‡Syndactyly (13 weeks'). Models were adjusted for severity of the fi rst falciparum malaria episode (asymptomatic, symptomatic, or hyperparasitaemic or severe), non-malaria febrile morbidity in the fi rst trimester, and year of fi rst consultation. See appendix p 9 for a table version of this fi gure, including univariable associations. *Hazard ratios are shown for treatments occurring before (<6 weeks' gestation) and during (≥6 and <13 weeks' gestation) the embryosensitive window. †Artemisinin rescue after quinine failure refers to artemisinin-based treatment in fi rst trimester following failure of fi rst-line treatment with quinine or quinine plus clindamycin. No miscarriages occurred in women who received artemisinin treatment after the embryo-sensitive window (≥13 and <14 weeks' gestation). We did a subgroup analysis excluding women with asymptomatic malaria (n=919); the association between artemisinin treatment and miscarriage changed by <5% (appendix p 9). We did a subgroup analysis in women attending before 2007 whose gestational age was estimated from ultrasound biometry, because the accuracy of gestational age estimates aff ects the accuracy of the gestation time of antimalarial treatment, and quinine plus clindamycin succeeded quinine monotherapy in 2007 (n=469); associations were in the same direction but of greater magnitude (appendix p 9). received fi rst-line quinine (table 2) . No newborns of mothers who received artemisinin in fi rst trimester had the skeletal or cardiovascular malformations as reported in animal studies.
Discussion
First-trimester falciparum malaria increases the risk of miscarriage, especially after recurrence, but this large prospective observational study found no evidence that fi rst-line treatment with an artemisinin derivative was associated with an increased risk of miscarriage or congenital malformations. Assessment of the safety of artemisinin treatment during pregnancy requires weighing the risks of falciparum malaria against those of its treatment. This is the fi rst study to estimate the eff ects of initial and recurrent fi rst-trimester malaria, its symptomatology, and its treatment on miscarriage.
Legitimate ethical concerns regarding randomisedcontrolled trials of fi rst-trimester artemisinin treatment have meant that only observational studies have been done to date, and these have not adjusted for confounding by indication and disease severity in assessing risks and benefi ts. 26 A major strength of this study is that it was possible to adjust for these important confounders by comparing with nearly 1000 women who received quinine treatment (appendix p 5). Left truncation, which adjusts for the temporally changing risks of miscarriage and varying gestation at presentation, was also accounted for since this is essential to avoid bias. 27 Nevertheless, this study still has limitations common to observational designs. Data were collected over a long period of time, relatively few fi rst-trimester artemisinin treatments were given, toxicities other than miscarriage and major mal formations detectable at birth from surface examination were not captured, and all artemisinin derivatives were analysed together. Several associations of considerable magnitude had wide CIs that crossed null, and we cannot rule out potential confounding eff ects of time and unmeasured variables, or residual confounding by disease severity. Furthermore, women with fi rst-trimester malaria were more likely to be lost to follow-up, raising the possibility of informative right censoring, but this would underestimate the eff ect of malaria (appendix p 5).
We noted no evidence that fi rst-line treatment with an artemisinin derivative increased the rate of miscarriage compared with fi rst-line treatment with quinine. There was a higher risk of miscarriage in women who received an artemisinin derivative during the putative embryosensitive window, but this might be explained at least in part by the administration of mefl oquine-artesunate at earlier gestations to symptomatic women in the routine outpatient clinics compared with the active surveillance of antenatal clinics. In rats, embryotoxicity of artesunate was attenuated when co-administered with mefl oquine. 28 Primates, including human beings, might be less sensitive to the eff ects of artemisinins because of diff erences in placentation and the visceral yolk sac, which could result in diff erent levels of embryonic exposure to artemisinins. 7, 29 Additionally, a 3-day artemisinin regimen means that the exposure period is relatively short in human beings because organogenesis is 3 days in rats but 3 months in human beings. 7, 29 Therefore, artemisinin-induced depletion of embryonic erythro blasts severe enough to cause miscarriage in rats might not translate to human beings, but could still cause congenital malformations.
We cannot draw fi rm conclusions on the possible eff ects of fi rst-trimester artemisinin treatment on congenital malformations because of relatively small numbers of treatments and cases. Furthermore, the prevalence of major congenital malformations is most likely an underestimation because only those detectable at birth from surface examination and heart auscultation were recorded routinely, and major malformations (particularly cardiovascular) are often not detected or confi rmed until later in life. Only four newborns whose mother received fi rst-line artemisinin treatment during fi rst trimester had a major congenital malformation, and the organ systems involved were inconsistent with the types of malformations induced by artemisinins in animal studies.
These results have important implications for malaria treatment and control policies, and future studies of artemisinin safety. Recurrent fi rst-trimester vivax malaria is associated with miscarriage, yet radical cure is not possible during pregnancy with currently available drugs. First-trimester falciparum malaria is strongly associated with miscarriage, especially after recurrence. We noted no evidence of harm associated with fi rst-line artemisinin treatment of fi rst-trimester falciparum malaria. Quinine is comparatively poorly tolerated and associated with a shorter time to recurrence than artemisinin in pregnant women. 30 Furthermore, women who received artemisinins following quinine failure were more likely to miscarry than those who received fi rst-line artemisinin treatment. Early and eff ective antimalarial treatment is imperative, especially because current preventive measures do not adequately cover early pregnancy. 3 Artemisinins are the most eff ective antimalarials available and have been recommended as fi rst-line treatment in the general population by the WHO since 2006. Yet, artemisinin safety in fi rst trimester is still a concern. This study contributes a further 183 welldocumented fi rst-trimester artemisinin treatments, and adds to a growing body of observational evidence supporting the use of artemisinins in the fi rst trimester of pregnancy. 3, 11, 12, [14] [15] [16] [17] [18] 22, 31 In view of the wide availability of artemisinin-based combination therapies, their excellent tolerability and effi cacy, the likely reduced future availability of quinine, and the rarity of congenital malformations, now might be the time to endorse the use of artemisinin derivatives for the treatment of fi rsttrimester falciparum malaria, accompanied by robust pharmacovigilance.
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